PMID- 27900045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210813
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 12
IP  - 5
DP  - 2016 Nov
TI  - MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer 
      cells via targeting FSCN1.
PG  - 3619-3625
AB  - MicroRNA (miR)-133b has been reported to act as a tumor suppressor in multiple 
      types of human cancers, including non small cell lung cancer (NSCLC). However, 
      the underlying mechanism by which miR-133b inhibits NSCLC metastasis remains 
      largely unclear. In the present study, reverse transcription-quantitative 
      polymerase chain reaction and western blotting were used to detect messenger RNA 
      and protein expression. A wound healing assay and transwell assay were used to 
      examine the cell migration and invasion. The expression level of miR-133b was 
      found to be significantly downregulated in NSCLC cell lines compared with normal 
      lung epithelial BEAS-2B cells. Further investigation identified fascin1 (FSCN1) 
      as a direct target of miR-133b in NSCLC cells. The expression of FSCN1 was 
      significantly increased in NSCLC cell lines compared with BEAS-2B cells, and its 
      protein expression was negatively regulated by miR-133b in NSCLC A549 cells. 
      Further investigation showed that the upregulation of miR-133b notably inhibited 
      NSCLC cell migration and invasion, while the overexpression of FSCN1 
      significantly promoted NSCLC cell migration and invasion. Furthermore, the 
      overexpression of FSCN1 reversed the suppressive effect of miR-133b 
      overexpression on NSCLC cell migration and invasion. Accordingly, the present 
      study suggests that miR-133b inhibits the migration and invasion of NSCLC cells 
      via directly targeting FSCN1, and thus may be used for the treatment of NSCLC 
      metastasis.
FAU - Yang, Xucheng
AU  - Yang X
AD  - Department of Orthopedics, Xiangya Hospital of Central South University, 
      Changsha, Hunan 410008, P.R. China.
FAU - Lei, Pengfei
AU  - Lei P
AD  - Department of Orthopedics, Xiangya Hospital of Central South University, 
      Changsha, Hunan 410008, P.R. China.
FAU - Huang, Yong
AU  - Huang Y
AD  - Department of Oncology, Xiangya Hospital of Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - Zhang, Zijian
AU  - Zhang Z
AD  - Department of Oncology, Xiangya Hospital of Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - Zhang, Yingying
AU  - Zhang Y
AD  - Department of Oncology, Xiangya Hospital of Central South University, Changsha, 
      Hunan 410008, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20160825
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
RIN - Oncol Lett. 2021 Sep;22(3):668. PMID: 34386090
PMC - PMC5104139
OTO - NOTNLM
OT  - fascin1
OT  - invasion
OT  - microRNA-133b
OT  - migration
OT  - non small cell lung cancer
EDAT- 2016/12/03 06:00
MHDA- 2016/12/03 06:01
PMCR- 2016/08/25
CRDT- 2016/12/01 06:00
PHST- 2015/03/22 00:00 [received]
PHST- 2016/04/13 00:00 [accepted]
PHST- 2016/12/01 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2016/12/03 06:01 [medline]
PHST- 2016/08/25 00:00 [pmc-release]
AID - OL-0-0-5044 [pii]
AID - 10.3892/ol.2016.5044 [doi]
PST - ppublish
SO  - Oncol Lett. 2016 Nov;12(5):3619-3625. doi: 10.3892/ol.2016.5044. Epub 2016 Aug 
      25.